Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (November 2021)
49 slides from Genprex's investor presentation, Nov 17, 2021
Slide 1: Reprogramming the Course of Cancer and Diabetes
©) Genprex REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX November 2021
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements contained inthis presentation gating matters thatare nt historical facts ae “forware-lookngstatements" within the meaning ofthe Private Secures Litigation ReformAccot 1295. Because uch statements are subecttorike ang uncertainties actual results may offer mately
Slide 3: GNPX at a Glance
GNPX AT A GLANCE Genprex,Inc. _ GNPX Nasdaq $205 ‘soem 308K 47808570 ‘$42 Million All date areas of November 15,2021, except for shores outsconding which is os of November 8, 2021, and cash which is os September 30, 2021. Genprex Nasdeq:GNPX 3.
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Novel gene therapies addressing cancer and diabetes [Aaoressing unmet mecieal need in large markets through the buldoutof a robust pipeline of new drug candidates and arug combinations. Leveraging o gene therapy platform: Genprex’s non-vtal Oncoprex® nanoparticle delivery syste
Slide 5: Executive Summary
EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES, + DEMONSTRATED CLINICAL ACHIEVEMENT + GENE THERAPY PLATFORM. + FIRST SYSTEMIC GENE THERAPY 7 . + INITIATED ONE LUNG CANCER CLINICAL TRIAL, EXPECT TO INITIATE SECOND USED FOR CANCER IN HUMANS CLINICAL TRIAL IN 2021 =o LARGE MARKETS AND UNMEL NEED. ‘ + W
Slide 6: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE wen’ pmecunuca, —«CUNICAL «= CLINICAL «CLINICAL eas PHASED PHASE 2 PHASE 3 =a | © Genprex Nasdoa:GNPX 6
Slide 7: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS. ‘+ Genprex’s oncology combination treatment '* Gene therapy drug candidate addresses Type 1 and approach utilizes targeted therapies and Type 2 diabetes. immunotherapies. '» May reduce or eliminate daily burden of chec
Slide 8: Oncology Program
Slide 9: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS OST L%.. CANCER TAGRISSO 2020 SALES NSCLC represents the majority of all lung cancers. ‘AstraZeneca’s highest grossing product. ‘WORLDWIDE CASES KEYTRUDA 2020 SALES ‘More than two million cases per year worldwide, ‘Merck's highest grossing product. NITED
Slide 10: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM The first systemic gene therapy delivery platform for cancer GENES ‘SYNERGIES Multiple tumor ‘Advanced approach suppressor genes using combination therapy CANCERS Multiple cancers Genprex Nasdeq:GNPX 10
Slide 11: Oncoprex Nanoparticle Delivery System
ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Positvely charged TUSC2 gene nanoparticle Cassette S) : » > > > ® 1) Negatively charged cancer cell Nanoparticle attaches, Cancer killing genes, Cell death to cancer cell integrate into cell Our non-viral, biode
Slide 12: Targeting Negative Surface Charges of Cancer Cells
TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN INNOVATIVE MEANS TO SELECTIVELY TARGET CANCER CELLS +The activities of glucose metabolism have a profound impact on the surface of cancer calls + Elevated glycolysis in cancer cells lead toa higher secretion of lactate + Secreted lactate ions rem
Slide 13: REQORSA Targets Cancer at Its Core
REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 4 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS — MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer p Nasaaq:GNEX 13
Slide 14: TUSC2 Inhibits Key Cell Signaling
TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS cork ‘Colt Survival Proliferation Nasaag:GNeK 14
Slide 15: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM immunomodulation of Carbo + Pembro + TUSC2 demonstrates rationale for the Acclaim-1 and Acclaim-2 clinical trials treating patients who show progression after treatment with Tagrisso or Keytruda. Note: Treg ond Myeloid els ore Immunasuppressive B A. Active T alts
Slide 16: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n= Maximum Tolerated
Slide 17: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS. PATIENT EGFR STATUS LINE C THE PY Positive (exon 18420) Complete Response Negative 2486 regression Target Lesion 30% regression one Target Lesion NeeaNe 18% regression all Target Lesion Positive (exon
Slide 18: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION ‘Swimmer Plot of Best Response, with Time on Study Negative 4 Negative 4 Positive (exon 18+20) 4 Negative 4 Negative 4 Negative 4 Negative 4 Negative Positive (exon 21) 4 Negative 4 Negative 4 Positive (exon 21) 4 EGFR status/mutation sD * Chemotherapy ‘4 Chemotherapy+i
Slide 19: AACR 21: REQORSA + Tagrisso Reduce Tumor Growth
AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN TAGRISSO-RESISTANT TUMORS f sen i ' Osimertinib+TUSC2 combination on H1975-OsiR tumors in NSG mice ‘Osimertinib+TUSC2 combination on 11975 tumors in NSG mice 0. & 2 200: ‘On O85 Of O82 08 O88 OF RAwDa Ea RCaua ECW Days Days se contour es) se comer i
Slide 20: Acclaim-1
ate Acclaim -1 + REQORSA In combination with AstraZeneca's Tagrisso for NSCLC ‘+ Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso 2-5 US, sites + -92 patients Phaze 1:9-18 patients Phase 2:74 patients Interim analysis at 25 events (Le. disease progression or death) I
Slide 21: Acclaim-1 Phase Components
PHASE 2 COMPONENT Acclaim -1 PRIMARY ENDPOINT 343 dose escalation of + Dose limiting toxicity REQORSA in combination with Tagrisso* PRIMARY ENDPOINT SECONDARY ENDPOINTS Randomized 1:1, opendabel + Progression free survival (PFS) + Overall response rate arm study of REQORSA in {BES improvement of REQ
Slide 22: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER Survival on Lung Metastasis Mode! , i os ‘TUSC2+anti-PD1 combination significantly prolonged TUSC2+anti-PD1 exhibit greater antitumor activity than aiTiN/All ia llne ereiesesetod
Slide 23: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda REQORSA + Keytruda + Chemo Strong antitumor immune responses of anti-PD1 were REQORSA+anti-PD1+chemo combination resulted found against PDX tumors developed in
Slide 24: AACR 21: REQORSA May Enhance First-Line Standard of Care
AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA MAY OVERCOME RESISTANCE TO KEYTRUDA + CHEMO COMBINATION REQORSA + Keytruda + Chemo + REQORSA enhances the efficacy of chemo-immunotherapy on KL-mutant lung metastases in humanized mice. + Triple combination demonstrated strong antitumo
Slide 25: Acclaim-2
alii Acclali m-2 REQORSA In combination with Merck & Co's Keytruda for NSCLC Interim analysis at 50 events (Le. disease Patients with metastatic NSCLC with prior history of Keytruda therapy progression or death) with at least 3-month clinical benefit + Phase 1 portion to be initiated by the end of t
Slide 26: Acclaim-2 Phase Components
rete jl? Acclaim: 2 PRIMARY ENDPOINT + 343 dose escalation of + Dose limiting toxicity REQORSA in combination with Keytruda PHASE 1 COMPONENT 5 PRIMARY ENDPOINT ‘SECONDARY ENDPOINTS TUG) ~ Randomized 21, operlabel, + ~Progression free survival (PES) ‘Overall response rate ag Daarm study of REQORSA I
Slide 27: Scaled-Up Clinical Grade Manufacturing
SCALED-UP CLINICAL GRADE MANUFACTURING MILESTONE POSITIONS COMPANY FOR SUCCESS IN LUNG CANCER THERAPEUTICS MARKET Achievement highlighted by important process improvements and significantly improved economies of scale. + Successful completion of technology transfer and scale-up of REQORSA + GMP prod
Slide 28: Diabetes Program
DIABETES PROGRAM
Slide 29: Diabetic Patients in Need of Advanced Treatment
DIABETIC PATIENTS IN NEED OF ADVANCED GPX-002 MAY euwinaTe te RY AR IN IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S’, or 10 percent of the U.S. population May replace daily burden of blood glucose monitoring and insulin replacement therapy, includ
Slide 30: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION AAV vector to deliver the Pdx1 and MafAgenes to Novel infusion process uses an endoscope and an 8 the pancreas. Transforms alpha cells in the pancreas into ny functional beta-like cells, which can produce insulin © © _ butar
Slide 31: Key Milestones Through 2021 & Beyond
KEY MILESTONES THROUGH 2021 & BEYOND COMPLETED Successful completion of technology transfer and scale-up of REQORSA Initiated site recruitment for both Acclaim clinical trials Reported preclinical data for REQORSA in, combination with targeted therapies and immunotherapies Received Centralized IRB A
Slide 32: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS = waar Hasan Nea og VA vosteg SNCTETNNE® newcuinis erases) S347 ten Lymphocytic Leukemia: easToeapeutcs MR nncag —-NECLESOOTECAL REA ray, sirvnnw Phase) £729 pram g SMX —=—Nasdog——— sole TumorLevemia TEPER Ae aseng) 890 Tuning scosstacnde PEROT pus 4 Twringre
Slide 33: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman, President & Chief Executive Officer + 30+ years of expertise in corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer frm RYAN CONFER, MS Chief Financial Officer + 10+ years of C-Leve
Slide 34: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD r HEMANT KUMAR, PHD. Senior Vice President, intellectual Property Chief Manufacturing & Technology Officer and Licensing + Recognized global expert in Chemistry, Manufacture + 20tyearsof expertise in biotech IP law, business and Controls (CMC) Te
Slide 35: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD PASI ANTERO JANNE JACK A ROTH reteset Meg Hard Medal Scat EWE O.FACS, Chairman pam eee ee Professor and Bud Johnson Distinguished Clinical for Thoracic Oncology; Scientific Director of the Belfer tie eee Poder oe eee Setar aeeeendrhans Bees Oncology: UT MD And
Slide 36: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD. iacHAGL MORSE me colbcenncereorics MD, MHS, FACP % MP. FACS + Professor of Medicine, Oislon of Medical Oncology % + Chief Executive Officer of Cancerinsighe LLC, 2 inthe Department of Surgery at Duke Unversity wii Seusue cancermmunateropy CRO + Research experti
Slide 37: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS. fi RODNEY VARNER, JD ® Chairman of the Board BRENT LONGNECKER + 30+ years.f expertise in corporate law, including Board Director ‘orporate governance, in biotech industry + Former owner of securities broker dealer frm + Chief Executive Officer, Lngnecker & Associate
Slide 38: We Believe in a Future of Transformational Patient Care
WE BELIEVE 215" CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS FAST TRACK DESIGNATION PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS: Nasaaq:GNEX 38
Slide 39: Genprex Contact
oO Genprex’ NASDAQ: GNPX (877)774-GNPX | investors@genprex.com Nasaaq: GNPX
Slide 40: Appendix
Slide 41: Two New Combination Clinical Trials
TWO NEW COMBINATION CLINICAL TRIALS — = KEYTRUDA ‘=i (pembrolizumab).. ONCOPREX® Nanoparticle Delivery/Sysem nanoparice livery system used in REQORSA™ Nasaaq:GNPX
Slide 42: Effects of Genetic Alterations in Suppressor Genes
EFFECTS OF GENETIC ALTERATIONS IN SUPPRESSOR GENES ‘The most common genetic alterations present in NSCLC are located in tumor-suppressor genes against which no targeted agents have been developed. + Regulation of Malignant Tumor Growth + insensitivity to Growth-inhibitory Signals + Evasions of Progr
Slide 43: Why Systemic Gene Therapy?
WHY SYSTEMIC GENE THERAPY? Lipid nanoparticles have been shown to encapsulate plasmid DNA, which allows the delivery of gene therapeutic agents intravenously to distant metastases Lipid nanoparticles with TUSC2 have up to a 33-fold affinity for cancer cells compared to healthy cells No need to attac
Slide 44: Why TUSC2?
WHY TUSC2? + 80% ofall lung cancer cells lack the TUSC2 tumor suppressor gene + Lossor reduction of TUSC2 expression is associated with significantly worse overall survival + Premalignant lesions express significantly lower levels of TUSC2 compared with normal bronchial epithelia © Genprex Nasaaq:GN
Slide 45: Viral vs. Non-Viral Vectors
VIRAL VS. NON-VIRAL VECTORS The most common viral vectors are adenoviruses andretroviruses + High level of transfection efficiency = Generally stable + Less specfcty of target cells = Can be immunogenic because capsid and viral proteins cause inflammation + Reported cases of death and causing leukem
Slide 46: Other Potential Cancer Indications
OTHER POTENTIAL CANCER INDICATIONS The region of the TUSC2 tumor suppressor gene is associated with chromosome 3p. In addition to NSCLC, other potential indications include: Thyroid Renal Breast Head & Neck Mesothelioma Ovary FUSY/TUSCZofeneyin mesothiome ondits tumerigenictrnaeritional ects: Mo! fo
Slide 47: REQORSA + Tagrisso Reduce Tumor Growth
REQORSA + TAGRISSO REDUCE TUMOR GROWTH EFFECT OF TAGRISSO (OSIMERTINIB) + TUSC2 ON A549-LUC METASTASIS ON NSG MICE (Osimertinib+TUSC2 on AS49 lung met in NSG mice Week 3 Torin eta x Figure 4A. TUSC2 combination wth Osimertin inhibits tumor growth and significantly prolongs survival A) tp: the treatm
Slide 48: Effect of REQORSA + Carbo + Keytruda on Humanized Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Carbo+Pembro Effect of CarbotPembro+TUSC2 on TUSC2 Carbo+Pembro__+TUSC2 ‘A549 lung met on Hu-NSG “% of change (wk2 vs WKS) tumor Intensity Pembrolizumob isthe generic nome for Keytrude. Nasaaq:GNexK 48
Slide 49: Effect of REQORSA + Carbo + Keytruda on Humanized Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of CarbotPembro+TUSC2 on A549 lung met on Hu-NSG 6*10°4-+ No treatment = Tusc2 wp 10° carbosPembro zg + CarborPembrortusc2 & 2x10. 3 Aa © 2x10°. $1.5 10°. F 4x08. bol «107. o 0. p14 28 D35 "** p= 0.0003 vs No treatme